Blair William & Co. IL Sells 20,449 Shares of Insulet Co. (NASDAQ:PODD)

Blair William & Co. IL trimmed its holdings in Insulet Co. (NASDAQ:PODD) by 15.9% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 108,077 shares of the medical instruments supplier’s stock after selling 20,449 shares during the quarter. Blair William & Co. IL owned 0.15% of Insulet worth $18,524,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Capital Research Global Investors boosted its holdings in Insulet by 19.7% during the 4th quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after acquiring an additional 1,556,455 shares during the period. Vanguard Group Inc. lifted its position in Insulet by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 8,029,608 shares of the medical instruments supplier’s stock valued at $1,742,264,000 after purchasing an additional 29,387 shares during the last quarter. Baillie Gifford & Co. grew its holdings in shares of Insulet by 18.9% in the first quarter. Baillie Gifford & Co. now owns 1,442,279 shares of the medical instruments supplier’s stock worth $247,207,000 after purchasing an additional 229,520 shares during the last quarter. Norges Bank bought a new position in shares of Insulet in the fourth quarter worth approximately $227,655,000. Finally, William Blair Investment Management LLC increased its stake in shares of Insulet by 3.7% in the first quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock worth $163,219,000 after buying an additional 33,579 shares during the period.

Analyst Upgrades and Downgrades

PODD has been the subject of several analyst reports. Canaccord Genuity Group increased their price target on shares of Insulet from $226.00 to $234.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Redburn Atlantic began coverage on shares of Insulet in a report on Thursday, May 30th. They set a “buy” rating and a $235.00 target price for the company. Jefferies Financial Group boosted their price target on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective for the company in a report on Tuesday, May 7th. Finally, Raymond James reduced their target price on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average target price of $239.18.

Insider Activity

In other Insulet news, Director Timothy J. Scannell sold 7,000 shares of Insulet stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.51, for a total value of $1,333,570.00. Following the completion of the sale, the director now owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, SVP Mark N. Field sold 1,500 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the transaction, the senior vice president now owns 12,875 shares in the company, valued at $2,574,485. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Timothy J. Scannell sold 7,000 shares of Insulet stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the completion of the sale, the director now directly owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The disclosure for this sale can be found here. Insiders have sold a total of 13,931 shares of company stock worth $2,636,286 over the last 90 days. 0.47% of the stock is currently owned by insiders.

Insulet Stock Up 0.0 %

Insulet stock traded up $0.07 during mid-day trading on Friday, hitting $195.03. The company had a trading volume of 653,925 shares, compared to its average volume of 845,942. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $289.73. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The stock’s 50 day moving average price is $191.00 and its two-hundred day moving average price is $185.13. The company has a market capitalization of $13.66 billion, a PE ratio of 59.08, a price-to-earnings-growth ratio of 3.56 and a beta of 1.16.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating the consensus estimate of $0.39 by $0.34. The company had revenue of $441.70 million for the quarter, compared to the consensus estimate of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. Insulet’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.23 EPS. As a group, sell-side analysts anticipate that Insulet Co. will post 3.11 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.